US2017246193A1PendingUtilityA1
Fatty acid acetylated salicylates and their uses
Assignee: CATABASIS PHARMACEUTICALS INCPriority: Jul 8, 2008Filed: Oct 3, 2016Published: Aug 31, 2017
Est. expiryJul 8, 2028(~2 yrs left)· nominal 20-yr term from priority
A61P 5/48A61P 9/10A61P 7/10A61P 9/04A61P 3/06A61P 9/00A61P 3/10A61P 7/00A61P 9/06A61P 25/16A61P 25/00A61P 25/14A61P 31/00A61P 3/00A61P 29/00A61P 27/02A61P 25/28A61P 1/00A61P 13/12A61P 21/02A61P 1/04A61P 17/00A61P 21/00A61K 31/232A61K 31/60C07C 69/94C07C 275/42C07D 295/192C07C 237/22C07C 235/60C07C 233/49C07C 235/52C07D 295/182A61K 31/609C07C 271/28C07C 233/18C07C 233/55C07C 69/86
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
Claims
exact text as granted — not AI-modified1 . A method of treating inflammation that is associated with a metabolic disorder, wherein the metabolic disorder is selected from the group consisting of cardiovascular disease, arrhythmia, coronary artery disease, and hypertriglyceridimia, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof,
wherein:
R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C 1 -C 3 alkyl), —N(C 1 -C 3 alkyl) 2 , —NH(C(O)C 1 -C 3 alkyl), —N(C(O)C 1 -C 3 alkyl) 2 , —C(O)H, —C(O)C 1 -C 3 alkyl, —C(O)OC 1 -C 3 alkyl, —C(O)NH 2 , —C(O)NH(C 1 -C 3 alkyl), —C(O)N(C 1 -C 3 alkyl) 2 , —O—C 1 -C 3 alkyl;
W 1 is NH and W 2 is selected from null, O, or NH;
- - - represents an optional bond that when present requires that Q is null;
a and c are each independently H, CH 3 , —OCH 3 , —OCH 2 CH 3 , or C(O)OH;
b is H, CH 3 , C(O)OH, or O—Z;
d is H or C(O)OH;
each n, o, p, and q is independently 0 or 1;
each Z is H or
with the proviso that there is at least one
in the compound;
each r is independently 2 or 3;
each s is independently 5 or 6;
each t is independently 0 or 1;
Q is null, C(O)CH 3 , Z,
e is H or any one of the side chains of the naturally occurring amino acids;
W 3 is null, O, or —N(R)—;
R is H or C 1 -C 3 alkyl; and
T is H, C(O)CH 3 , or Z.
2 . The method of claim 1 , wherein the compound is a compound wherein W 2 is NH.
3 . The method of claim 2 , wherein the compound is a compound wherein r is 2, s is 6, t is 1, and Z is
4 . The method of claim 3 , wherein the compound is
5 . The method of claim 1 , wherein the compound is a compound wherein Q is Z.
6 . The method of claim 1 , wherein the compound is a compound wherein Q is
7 . The method of claim 1 , wherein the compound is a compound wherein Q is Z and Z is H.
8 . The method of claim 1 , wherein the compound is a compound wherein two of n, o, p, and q are each 1.
9 . The method of claim 1 , wherein the compound is a compound wherein r is 3, s is 5, t is 1, and Z is
10 . The method of claim 1 , wherein the compound is
11 . A method of treating inflammation that is associated with a neurodegenerative disorder selected from the group consisting of Huntington's Disease, infectious meningitis, encephalomyelitis, Parkinson's disease, and encephalitis, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof,
wherein:
R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of H, Cl, F, CN, —NH(C 1 -C 3 alkyl), —N(C 1 -C 3 alkyl) 2 , —NH(C(O)C 1 -C 3 alkyl), —N(C(O)C 1 -C 3 alkyl) 2 , —C(O)H, —C(O)C 1 -C 3 alkyl, —C(O)OC 1 -C 3 alkyl, —C(O)NH 2 , —C(O)NH(C 1 -C 3 alkyl), —C(O)N(C 1 -C 3 alkyl) 2 , —O—C 1 -C 3 alkyl:
W 1 is NH and W 2 is selected from null, O, or NH;
- - - represents an optional bond that when present requires that Q is null;
a and c are each independently H, CH 3 , —OCH 3 , —OCH 2 CH 3 , or C(O)OH;
b is H, CH 3 , C(O)OH, or O—Z;
d is H or C(O)OH;
each n, o, p, and q is independently 0 or 1;
each Z is H or
with the proviso that there is at least one
in the compound;
each r is independently 2 or 3;
each s is independently 5 or 6;
each t is independently 0 or 1;
Q is null, C(O)CH 3 , Z,
e is H or any one of the side chains of the naturally occurring amino acids;
W 3 is null, O, or —N(R)—;
R is H or C 1 -C 3 alkyl; and
T is H, C(O)CH 3 , or Z.
12 . The method of claim 11 , wherein the compound is a compound wherein W 2 is NH.
13 . The method of claim 11 , wherein the compound is a compound wherein r is 2, s is 6, t is 1, and Z is
14 . The method of claim 11 , wherein the compound is
15 . The method of claim 11 , wherein the compound is a compound wherein Q is Z.
16 . The method of claim 11 , wherein the compound is a compound wherein Q is
17 . The method of claim 11 , wherein the compound is a compound wherein Q is Z and Z is H.
18 . The method of claim 11 , wherein the compound is a compound wherein two of n, o, p, and q are each 1.
19 . The method of claim 11 , wherein the compound is a compound wherein r is 3, s is 5, t is 1, and Z is
20 . The method of claim 11 , wherein the compound is
21 - 30 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.